BR112015010703A8 - Uso de uma composição farmacêutica e composição farmacêutica - Google Patents

Uso de uma composição farmacêutica e composição farmacêutica

Info

Publication number
BR112015010703A8
BR112015010703A8 BR112015010703A BR112015010703A BR112015010703A8 BR 112015010703 A8 BR112015010703 A8 BR 112015010703A8 BR 112015010703 A BR112015010703 A BR 112015010703A BR 112015010703 A BR112015010703 A BR 112015010703A BR 112015010703 A8 BR112015010703 A8 BR 112015010703A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
compositions
tocotrienol
tocotrienols
Prior art date
Application number
BR112015010703A
Other languages
English (en)
Other versions
BR112015010703A2 (pt
BR112015010703B1 (pt
Inventor
Tong Glenn
Original Assignee
Gordagen Pharmaceuticals Pty Ltd
Invictus Biotechnology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by Gordagen Pharmaceuticals Pty Ltd, Invictus Biotechnology Pty Ltd filed Critical Gordagen Pharmaceuticals Pty Ltd
Publication of BR112015010703A2 publication Critical patent/BR112015010703A2/pt
Publication of BR112015010703A8 publication Critical patent/BR112015010703A8/pt
Publication of BR112015010703B1 publication Critical patent/BR112015010703B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA, USOS DE PELO MENOS UM TOCOTRIENOL OU DERIVADO DESTE, E USOS DE UMA COMPOSIÇÃO FARMACÊUTICA. A presente invenção se refere às composições farmacêuticas formuladas para administração transmucosal que incluem pelo menos um tocotrienóis ou derivados destes e os usos destas composições.
BR112015010703-6A 2012-11-13 2013-11-13 uso de uma composição farmacêutica e composição farmacêutica BR112015010703B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUAU2012904937 2012-11-13
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AUAU2012905406 2012-12-11
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (3)

Publication Number Publication Date
BR112015010703A2 BR112015010703A2 (pt) 2017-07-11
BR112015010703A8 true BR112015010703A8 (pt) 2018-08-14
BR112015010703B1 BR112015010703B1 (pt) 2021-02-17

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010703-6A BR112015010703B1 (pt) 2012-11-13 2013-11-13 uso de uma composição farmacêutica e composição farmacêutica

Country Status (23)

Country Link
US (2) US10675265B2 (pt)
EP (1) EP2919777B1 (pt)
JP (3) JP6460998B2 (pt)
KR (1) KR20150082109A (pt)
CN (2) CN104582700B (pt)
AU (1) AU2013344817B2 (pt)
BR (1) BR112015010703B1 (pt)
CA (1) CA2891164C (pt)
DK (1) DK2919777T3 (pt)
ES (1) ES2778065T3 (pt)
HK (1) HK1207295A1 (pt)
IL (1) IL238727A0 (pt)
IN (1) IN2015DN04006A (pt)
MY (1) MY177940A (pt)
NZ (1) NZ628963A (pt)
PE (1) PE20151518A1 (pt)
PH (1) PH12015501048A1 (pt)
PL (1) PL2919777T3 (pt)
PT (1) PT2919777T (pt)
RU (1) RU2015120181A (pt)
SG (1) SG11201503640WA (pt)
WO (1) WO2014075135A1 (pt)
ZA (1) ZA201504191B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
KR20150082109A (ko) * 2012-11-13 2015-07-15 고다겐 파마슈티컬스 피티와이 엘티디 토코트리에놀의 경점막 전달
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US20170128412A1 (en) * 2015-08-11 2017-05-11 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
US20240139100A1 (en) * 2020-12-04 2024-05-02 Invictus Biotechnology Pty Ltd Transmucosal delivery of tocotrienols

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) * 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1270004B1 (en) 2000-03-31 2010-06-09 Eisai R&D Management Co., Ltd. Use of gamma-tocotrienol as diuretic
JP2001342133A (ja) * 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
US6608103B2 (en) * 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
JP4447198B2 (ja) * 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物
JP4903558B2 (ja) * 2003-02-14 2012-03-28 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレイティド ガンマ−トコトリエノールによる放射線防護
EP1617724B1 (en) * 2003-04-10 2014-08-20 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
US20060013901A1 (en) * 2004-05-26 2006-01-19 Kgk Synergize Inc. Compositions comprising flavonoids and tocotrienols and methods thereof
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
WO2009126866A2 (en) * 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
US20120058962A1 (en) 2009-05-20 2012-03-08 Lingual Conseqna Pty Ltd. Buccal and/or sublingual therapeutic formulation
EA201200054A1 (ru) * 2009-06-25 2012-05-30 Эмпэр Лайф Сайнсиз, Инк. Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
NO2470168T3 (pt) * 2009-08-26 2018-06-30
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
MX2018007514A (es) 2011-02-18 2022-10-21 Biolingus Ip Llc Proceso para preparar productos que comprenden activos estabilizados y composiciones que los comprenden.
EP3415139B8 (en) * 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
KR20150082109A (ko) * 2012-11-13 2015-07-15 고다겐 파마슈티컬스 피티와이 엘티디 토코트리에놀의 경점막 전달

Also Published As

Publication number Publication date
SG11201503640WA (en) 2015-06-29
PH12015501048A1 (en) 2015-07-27
WO2014075135A1 (en) 2014-05-22
MY177940A (en) 2020-09-28
PE20151518A1 (es) 2015-11-25
US20150265570A1 (en) 2015-09-24
ZA201504191B (en) 2016-11-30
BR112015010703A2 (pt) 2017-07-11
KR20150082109A (ko) 2015-07-15
US11331302B2 (en) 2022-05-17
JP6460998B2 (ja) 2019-01-30
JP6978392B2 (ja) 2021-12-08
JP2016503407A (ja) 2016-02-04
EP2919777A4 (en) 2016-05-18
EP2919777A1 (en) 2015-09-23
AU2013344817B2 (en) 2015-09-17
JP2019031504A (ja) 2019-02-28
CA2891164C (en) 2021-02-09
CN112451518A (zh) 2021-03-09
NZ628963A (en) 2017-02-24
EP2919777B1 (en) 2020-01-08
BR112015010703B1 (pt) 2021-02-17
HK1207295A1 (en) 2016-01-29
PT2919777T (pt) 2020-03-30
CA2891164A1 (en) 2014-05-22
CN104582700B (zh) 2021-01-05
RU2015120181A (ru) 2017-01-10
JP2021008509A (ja) 2021-01-28
IL238727A0 (en) 2015-06-30
DK2919777T3 (da) 2020-03-09
CN104582700A (zh) 2015-04-29
US20200246306A1 (en) 2020-08-06
US10675265B2 (en) 2020-06-09
ES2778065T3 (es) 2020-08-07
PL2919777T3 (pl) 2020-07-13
IN2015DN04006A (pt) 2015-10-02
AU2013344817A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
BR112015010703A8 (pt) Uso de uma composição farmacêutica e composição farmacêutica
MX2018004175A (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112018007977A2 (pt) inibidores de ferroportina inovadores
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
BR112015022566A2 (pt) composto e composição farmacêutica
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015003655A2 (pt) composto; uso de um composto; e composição farmacêutica
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112012009310B8 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
BR112017012005A2 (pt) compostos orgânicos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: INVICTUS BIOTECHNOLOGY PTY LTD (AU)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2013, OBSERVADAS AS CONDICOES LEGAIS.